Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL - Free Report) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the specialty pharmaceutical company's stock. HC Wainwright also issued estimates for Collegium Pharmaceutical's Q1 2025 earnings at $1.20 EPS, Q2 2025 earnings at $1.48 EPS, Q3 2025 earnings at $1.75 EPS, Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

Several other equities research analysts have also weighed in on the company. Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded up $0.15 during trading on Monday, hitting $29.71. 249,570 shares of the stock were exchanged, compared to its average volume of 438,298. The company's fifty day simple moving average is $30.36 and its 200-day simple moving average is $32.45. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $935.45 million, a price-to-earnings ratio of 12.81 and a beta of 0.99. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29.

Remove Ads

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Sell-side analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock worth $3,243,594 in the last three months. Insiders own 3.98% of the company's stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares during the last quarter. Principal Financial Group Inc. boosted its position in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after buying an additional 64,958 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after buying an additional 5,480 shares during the period. Geode Capital Management LLC raised its position in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock worth $29,974,000 after acquiring an additional 5,464 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after acquiring an additional 116,327 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.